Stock AnalizMesoblast Ltd. MESO
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026
Mesoblast Ltd. (MESO) is a healthcare company listed in the US with a market value of about $1.7B. In fiscal year 2025 it had revenue of $17M and net income of -$102M, a net margin of -593.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17M | $6M | $8M | $10M | $7M | $32M | $17M | $17M | $2M | $43M |
| Net income | -$102M | -$88M | -$82M | -$91M | -$99M | -$78M | -$90M | -$35M | -$77M | -$4M |
| Free cash flow | -$51M | -$49M | -$64M | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.79 | $-0.68 | $-0.63 | $-0.70 | $-0.76 | $-0.60 | $-0.69 | $-0.27 | $-0.59 | $-0.03 |
| Net margin | -593.9% | -1490.3% | -1091.7% | -894.6% | -1329.2% | -242.4% | -537.0% | -203.5% | -3184.7% | -9.7% |
| ROIC | -8.8% | -11.3% | -10.2% | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $37.00, 179% above the current price; targets range from $35.00 to $39.00; the consensus rating is “none”; expected EPS is $-0.06 for the fiscal year ending June 30, 2027.
Frequently asked questions
Is Mesoblast stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mesoblast pay a dividend?
Not currently.
Is Mesoblast a good stock to buy?
We do not give buy or sell advice. Mesoblast scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.